REG - PureTech Health PLC - PDMR Notification RSU Vesting

Puretech HealthAnnouncement

06/03/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240306:nRSF6972Fa&default-theme=true

RNS Number : 6972F  PureTech Health PLC  06 March 2024

6 March 2024

PureTech Health plc

 

PDMR Notifications

 

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to giving life to new classes
of medicine to change the lives of patients with devastating diseases,
announces that awards of restricted share units ("RSUs") granted by PureTech
on 21 July 2021 to certain directors and other persons discharging managerial
responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP")
vested on 4 March 2024 following satisfaction of performance conditions
measured over the three year period to 31 December 2023.

Each PDMR received vested ordinary shares (after deduction of shares for
payroll taxes) on 5 March 2024. The market price per ordinary share in the
Company used to calculate the amount payable to the PDMRs and the amount of
shares to be issued to PDMRs was 200 pence, being the average closing price of
the Company's shares over the three-trading day period immediately preceding
the settlement, and the exchange rate used to calculate the cash payment and
amount of share settlement was £1: $1.26.

The Company's total issued ordinary share capital is 289,468,159 shares after
the share issuance to the PDMRs, 19,259,058 shares of which are held in
treasury by the Company.

PDMR Notification

 

The information contained in the below notification is disclosed in accordance
with Article 19 of the EU Market Abuse Regulation.

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Daphne Zohar

                                                                  Bharatt Chowrira

                                                                  Eric Elenko
 2   Reason for the notification
 a)  Position/status                                              Daphne Zohar - Chief Executive Officer
                                                                  Bharatt Chowrira - President and Chief Business, Financial and Operating Officer
                                                                  Eric Elenko - Chief Innovation and Strategy Officer
 b)  Initial notification/Amendment                               Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         PureTech Health plc
 b)  LEI                                                          213800LVPDNO2Z9T9I39
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of PureTech Health plc

                                                                  ISIN GB00BY2Z0H74
 b)  Nature of the transaction                                    Issuance of ordinary shares in net settlement of certain vested RSUs under the
                                                                  PureTech Health Performance Share Plan, after retentions in respect of payroll
                                                                  taxes.
 c)  Price(s) and volume(s)                                       Recipient         Price     Amount
                                                                  Daphne Zohar      0.01 GBP  148,482 ordinary shares
                                                                  Bharatt Chowrira  0.01 GBP  59,287 ordinary shares
                                                                  Eric Elenko       0.01 GBP  51,591 ordinary shares
 d)  Aggregated information                                       Price     Aggregate Volume

- Aggregated volume                                         0.01 GBP  259,360 ordinary shares

- Price
 e)  Date of the transaction                                      5 March 2024
 f)  Place of the transaction                                     London Stock Exchange (XLON)

b)

Nature of the transaction

Issuance of ordinary shares in net settlement of certain vested RSUs under the
PureTech Health Performance Share Plan, after retentions in respect of payroll
taxes.

c)

Price(s) and volume(s)

 Recipient         Price     Amount
 Daphne Zohar      0.01 GBP  148,482 ordinary shares
 Bharatt Chowrira  0.01 GBP  59,287 ordinary shares
 Eric Elenko       0.01 GBP  51,591 ordinary shares

d)

Aggregated information

 -  Aggregated volume

 -  Price

 Price     Aggregate Volume
 0.01 GBP  259,360 ordinary shares

e)

Date of the transaction

5 March 2024

f)

Place of the transaction

London Stock Exchange (XLON)

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 28 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both US
FDA clearance and European marketing authorization and a third (KarXT) that
has been filed for FDA approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X
(formerly Twitter) @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUPUCCWUPCGAA